Oncology & Cancer

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who ...

Oncology & Cancer

Immunotherapy drug bolsters head and neck cancer treatment

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

page 1 from 6